# ProQR Therapeutics N.V. (PRQR)

Source: https://www.quantisnow.com/company/PRQR
Generated: 2026-11-10T12:32:39.199Z

- Ticker: PRQR
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2014
- SEC CIK: 0001612940
- Website: proqr.com

## About

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It is primarily developing sepofarsen that is in phase II/III illuminate trial for treating leber's congenital amaurosis 10 disease; QR-421a, which is in phase I/II stellar trial for usher syndrome type 2 and non-syndromic retinitis pigmentosa; QR-1123 that is in phase I/II aurora trial for the treatment of autosomal dominant retinitis pigmentosa; and QR-504a, which is in first clinical trial for the treatment of fuchs endothelial corneal dystrophy. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

## Latest PRQR news and filings

- 2026-10-30 20:01 UTC [SEC Form 6-K] [Amendment: SEC Form 6-K/A filed by ProQR Therapeutics N.V.](https://www.quantisnow.com/insight/amendment-sec-form-6-ka-filed-by-proqr-therapeutics-nv-6765134)
- 2026-10-28 12:05 UTC [SEC Form 6-K] [SEC Form 6-K filed by ProQR Therapeutics N.V.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-proqr-therapeutics-nv-6760624)
- 2026-09-23 12:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by ProQR Therapeutics N.V.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-proqr-therapeutics-nv-6723675)
- 2026-09-23 12:00 UTC [Leadership Update] [ProQR Announces Appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to join the Board of Directors as Strategic AI Advisor](https://www.quantisnow.com/insight/proqr-announces-appointment-of-chris-hart-as-chief-data-and-6723632)
- 2026-09-09 12:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by ProQR Therapeutics N.V.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-proqr-therapeutics-nv-6709339)
- 2026-09-09 12:00 UTC [ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026](https://www.quantisnow.com/insight/proqr-announces-first-participant-dosed-in-phase-1-study-of-6709280)
- 2026-09-02 12:00 UTC [Conference Announcement] [ProQR to Participate in Upcoming Investor Conferences in September 2026](https://www.quantisnow.com/insight/proqr-to-participate-in-upcoming-investor-conferences-in-september-2026-6702339)
- 2026-08-20 11:46 UTC [Analyst Coverage Initiated] [BofA Securities initiated coverage on ProQR Therapeutics with a new price target](https://www.quantisnow.com/insight/bofa-securities-initiated-coverage-on-proqr-therapeutics-with-a-new-6689405)
- 2026-08-13 11:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by ProQR Therapeutics N.V.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-proqr-therapeutics-nv-6679195)
- 2026-08-13 11:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by ProQR Therapeutics N.V.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-proqr-therapeutics-nv-6679192)
- 2026-08-13 11:00 UTC [Public Offering] [ProQR Announces Second Quarter 2026 Operating and Financial Results](https://www.quantisnow.com/insight/proqr-announces-second-quarter-2026-operating-and-financial-results-6679153)
- 2026-08-03 20:01 UTC [Insider Buy] [Chief Executive Officer De Boer Daniel Anton bought $353,960 worth of Ordinary Shares (200,000 units at $1.77), increasing direct ownership by 67% to 500,000 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-de-boer-daniel-anton-bought-353960-worth-6659524)
- 2026-07-29 13:48 UTC [SEC Form SCHEDULE 13G filed by ProQR Therapeutics N.V.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-proqr-therapeutics-nv-6653033)
- 2026-07-24 20:30 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by ProQR Therapeutics N.V.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-proqr-therapeutics-nv-6648453)
- 2026-07-21 12:00 UTC [Insider Buy] [Director Filius Bart bought $257,925 worth of Ordinary Shares (150,000 units at $1.72), increasing direct ownership by 100% to 300,000 units (SEC Form 4)](https://www.quantisnow.com/insight/director-filius-bart-bought-257925-worth-of-ordinary-shares-150000-6643255)
- 2026-07-16 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by ProQR Therapeutics N.V.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-proqr-therapeutics-nv-6638860)
- 2026-07-15 20:30 UTC [SEC Form 424B5] [SEC Form 424B5 filed by ProQR Therapeutics N.V.](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-proqr-therapeutics-nv-6638437)
- 2026-07-13 12:00 UTC [Insider Buy] [Chief Executive Officer De Boer Daniel Anton bought $261,000 worth of Ordinary Shares (150,000 units at $1.74), increasing direct ownership by 100% to 300,000 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-de-boer-daniel-anton-bought-261000-worth-6634861)
- 2026-07-08 18:55 UTC [Insider Buy] [Chief Executive Officer De Boer Daniel Anton bought $238,500 worth of Ordinary Shares (150,000 units at $1.59) (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-de-boer-daniel-anton-bought-238500-worth-6631398)
- 2026-07-06 20:10 UTC [SEC Form F-3 filed by ProQR Therapeutics N.V.](https://www.quantisnow.com/insight/sec-form-f-3-filed-by-proqr-therapeutics-nv-6628148)
- 2026-06-30 20:02 UTC [SEC Form 4] [Amendment: SEC Form 4 filed by Director Hinsch Gylvin Lykke](https://www.quantisnow.com/insight/amendment-sec-form-4-filed-by-director-hinsch-gylvin-lykke-6620694)
- 2026-06-30 20:01 UTC [Insider Buy] [Director Filius Bart bought $231,000 worth of Ordinary Shares (150,000 units at $1.54) (SEC Form 4)](https://www.quantisnow.com/insight/director-filius-bart-bought-231000-worth-of-ordinary-shares-150000-6620681)
- 2026-06-26 00:15 UTC [SEC Form 6-K] [SEC Form 6-K filed by ProQR Therapeutics N.V.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-proqr-therapeutics-nv-6616600)
- 2026-06-26 00:12 UTC [SEC Form 424B5] [SEC Form 424B5 filed by ProQR Therapeutics N.V.](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-proqr-therapeutics-nv-6616599)
- 2026-06-25 10:35 UTC [Public Offering] [ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement](https://www.quantisnow.com/insight/proqr-prices-500-million-underwritten-registered-direct-offering-and-concurrent-6615010)
- 2026-06-25 10:30 UTC [SEC Form 6-K] [SEC Form 6-K filed by ProQR Therapeutics N.V.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-proqr-therapeutics-nv-6615006)
- 2026-06-25 10:25 UTC [ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform](https://www.quantisnow.com/insight/proqr-announces-positive-phase-1-target-engagement-data-for-ax-0810-6614983)
- 2026-06-03 20:01 UTC [SEC Form 4] [SEC Form 4 filed by Director Hinsch Gylvin Lykke](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-hinsch-gylvin-lykke-6586634)
- 2026-06-02 20:01 UTC [SEC Form 3] [SEC Form 3 filed by new insider Hinsch Gylvin Lykke](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-hinsch-gylvin-lykke-6584009)
- 2026-06-02 20:01 UTC [SEC Form 6-K] [SEC Form 6-K filed by ProQR Therapeutics N.V.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-proqr-therapeutics-nv-6584003)
- 2026-05-12 11:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by ProQR Therapeutics N.V.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-proqr-therapeutics-nv-6546570)
- 2026-05-12 11:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by ProQR Therapeutics N.V.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-proqr-therapeutics-nv-6546555)
- 2026-05-12 11:00 UTC [ProQR Announces First Quarter 2026 Operating and Financial Results](https://www.quantisnow.com/insight/proqr-announces-first-quarter-2026-operating-and-financial-results-6546518)
- 2026-05-11 12:00 UTC [ProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of its Axiomer™ RNA Editing Platform](https://www.quantisnow.com/insight/proqr-announces-multiple-upcoming-scientific-conference-presentations-highlighting-the-breadth-6543765)
- 2026-05-04 12:05 UTC [SEC Form 6-K] [SEC Form 6-K filed by ProQR Therapeutics N.V.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-proqr-therapeutics-nv-6528121)
- 2026-05-04 12:00 UTC [ProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026](https://www.quantisnow.com/insight/proqr-announces-annual-general-meeting-of-shareholders-to-be-held-6528025)
- 2026-04-30 12:10 UTC [SEC Form 6-K] [SEC Form 6-K filed by ProQR Therapeutics N.V.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-proqr-therapeutics-nv-6523068)
- 2026-04-30 12:00 UTC [ProQR Announces Nomination of Dr. Lykke Hinsch Gylvin to its Board of Directors](https://www.quantisnow.com/insight/proqr-announces-nomination-of-dr-lykke-hinsch-gylvin-to-its-6522932)
- 2026-04-08 20:06 UTC [SEC Form 6-K] [SEC Form 6-K filed by ProQR Therapeutics N.V.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-proqr-therapeutics-nv-6492867)
- 2026-04-08 20:00 UTC [ProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst Event](https://www.quantisnow.com/insight/proqr-highlights-pipeline-expansion-and-multiple-upcoming-clinical-catalysts-at-6492742)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/PRQR
- Earnings history: https://www.quantisnow.com/earnings/PRQR
- Dividend history: https://www.quantisnow.com/dividends/PRQR
- Insider transactions: https://www.quantisnow.com/insiders/PRQR
- Options chain: https://www.quantisnow.com/options/PRQR
- SEC 8-K filings only: https://www.quantisnow.com/company/PRQR/8-k
- RSS and alerts for PRQR: https://www.quantisnow.com/docs/rss-feeds.md